Trading Signals: SAGE Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Fri. Dec. 22, 2023)(SAGE Therapeutics Inc)
| SAGE latest price $168.2000 (-0.21%) ($166.1000 - $168.8800) on Mon. Jul. 23, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.27% (three month average) | RSI | 91 | Latest Price | $168.2000(-0.21%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | SAGE advances 2.8% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Normal for small cap. | Correlated ETFs | Broad market will support SAGE advance at 0% a week (0% probability) IBB(50%) XBI(47%) IWO(46%) IWC(43%) IWM(42%) | Factors Impacting SAGE price | SAGE will decline at least -1.635% in a week (0% probabilities). VXX(-11%) VIXM(-11%) UUP(-11%) TLT(-7%) SHY(-4%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.635% (StdDev 3.27%) | Hourly BBV | 0 () | Intraday Trend | 0.1% | | | |
|
5 Day Moving Average | $168.49(-0.17%) | 10 Day Moving Average | $167.65(0.33%) | 20 Day Moving Average | $162.01(3.82%) | To recent high | -4.3% | To recent low | 19.8% | Market Cap | $8.735b | | | | SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA. |